dc.contributor.author | Wilson, JM | |
dc.contributor.author | Dearnaley, DP | |
dc.contributor.author | Syndikus, I | |
dc.contributor.author | Khoo, V | |
dc.contributor.author | Birtle, A | |
dc.contributor.author | Bloomfield, D | |
dc.contributor.author | Choudhury, A | |
dc.contributor.author | Graham, J | |
dc.contributor.author | Ferguson, C | |
dc.contributor.author | Malik, Z | |
dc.contributor.author | Money-Kyrle, J | |
dc.contributor.author | O'Sullivan, JM | |
dc.contributor.author | Panades, M | |
dc.contributor.author | Parker, C | |
dc.contributor.author | Rimmer, Y | |
dc.contributor.author | Scrase, C | |
dc.contributor.author | Staffurth, J | |
dc.contributor.author | Stockdale, A | |
dc.contributor.author | Cruickshank, C | |
dc.contributor.author | Griffin, C | |
dc.contributor.author | Hall, E | |
dc.contributor.author | CHHiP Investigators, | |
dc.date.accessioned | 2018-05-08T10:10:12Z | |
dc.date.issued | 2018-04-01 | |
dc.identifier.citation | International journal of radiation oncology, biology, physics, 2018, 100 (5), pp. 1179 - 1189 | |
dc.identifier.issn | 0360-3016 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1670 | |
dc.identifier.eissn | 1879-355X | |
dc.identifier.doi | 10.1016/j.ijrobp.2018.01.016 | |
dc.description.abstract | PURPOSE: Outcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides a large, prospectively collected, contemporary dataset in which to explore outcomes by age. METHODS AND MATERIALS: CHHiP participants received 3 to 6 months of androgen deprivation therapy and were randomly assigned (1:1:1) to receive 74 Gy in 37 fractions (conventional fractionation), 60 Gy in 20 fractions, or 57 Gy in 19 fractions. Toxicity was assessed using clinician-reported outcome (CRO) and patient-reported outcome questionnaires. Participants were categorized as aged < 75 years or ≥ 75 years. Outcomes were compared by age group. RESULTS: Of 3216 patients, 491 (15%) were aged ≥ 75 years. There was no difference in biochemical or clinical failure rates between the groups aged < 75 years and ≥ 75 years for any of the fractionation schedules. In the group aged ≥ 75 years, biochemical or clinical failure-free rates favored hypofractionation, and at 5 years, they were 84.7% for 74 Gy, 91% for 60 Gy, and 87.7% for 57 Gy. The incidence of CRO (grade 3) acute bowel toxicity was 2% in both age groups. The incidence of grade 3 acute bladder toxicity was 8% in patients aged < 75 years and 7% in those aged ≥ 75 years. The 5-year cumulative incidence of CRO grade ≥ 2 late bowel side effects was similar in both age groups. However, in the group aged ≥ 75 years, there was a suggestion of a higher cumulative incidence of bowel bother (small or greater) with 60 Gy compared with 74 Gy and 57 Gy. Patient-reported bladder bother was slightly higher in the group aged ≥ 75 years than the group aged < 75 years, and there was a suggestion of a lower cumulative incidence of bladder bother with 57 Gy compared with 74 Gy and 60 Gy in patients aged ≥ 75 years, which was not evident in those aged < 75 years. CONCLUSIONS: Hypofractionated radiation therapy appears to be well tolerated and effective in men aged ≥ 75 years. The 57-Gy schedule has potential advantages in that it may moderate long-term side effects without compromising treatment efficacy in this group. | |
dc.format | Print-Electronic | |
dc.format.extent | 1179 - 1189 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE INC | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | CHHiP Investigators | |
dc.subject | Intestines | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Radiation Injuries | |
dc.subject | Androgen Antagonists | |
dc.subject | Incidence | |
dc.subject | Prospective Studies | |
dc.subject | Age Factors | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Male | |
dc.subject | Radiotherapy, Intensity-Modulated | |
dc.subject | Urinary Bladder | |
dc.subject | Radiation Dose Hypofractionation | |
dc.title | The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-01-03 | |
rioxxterms.versionofrecord | 10.1016/j.ijrobp.2018.01.016 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-04 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | International journal of radiation oncology, biology, physics | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/ICR-CTSU Urology and Head and Neck Trials Team | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 100 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
icr.researchteam | ICR-CTSU Urology and Head and Neck Trials Team | |
icr.researchteam | Clinical Academic Radiotherapy (Dearnaley) | |
dc.contributor.icrauthor | Dearnaley, David | |
dc.contributor.icrauthor | Cruickshank, Clare | |
dc.contributor.icrauthor | Griffin, Clare | |
dc.contributor.icrauthor | Hall, Emma | |